Cardiol Therapeutics (NASDAQ:CRDL – Get Free Report) and Gilead Sciences (NASDAQ:GILD – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.
Profitability
This table compares Cardiol Therapeutics and Gilead Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiol Therapeutics | N/A | -194.40% | -129.07% |
| Gilead Sciences | 0.45% | 29.00% | 9.83% |
Volatility & Risk
Cardiol Therapeutics has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiol Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
| Gilead Sciences | 0 | 12 | 11 | 3 | 2.65 |
Cardiol Therapeutics currently has a consensus price target of $8.75, suggesting a potential upside of 440.12%. Gilead Sciences has a consensus price target of $95.41, suggesting a potential upside of 5.79%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Cardiol Therapeutics is more favorable than Gilead Sciences.
Institutional & Insider Ownership
12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 0.2% of Gilead Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Cardiol Therapeutics and Gilead Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiol Therapeutics | $60,000.00 | 2,203.28 | -$20.84 million | ($0.39) | -4.15 |
| Gilead Sciences | $27.12 billion | 4.15 | $5.67 billion | $0.09 | 1,002.11 |
Gilead Sciences has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Gilead Sciences beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.
About Cardiol Therapeutics
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
About Gilead Sciences
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Receive News & Ratings for Cardiol Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiol Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
